Physician profile
Mark A Marconi
NPI 1982656583
$4,611.31
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $1,208 · 2021: $1,167 · 2022: $1,270 · 2023: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.12 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $581.32 | 2019-2022 | |
| Novo Nordisk INC | $497.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.86 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $352.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $321.81 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $203.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.19 | 2019-2021 | |
| Allergan, INC. | $161.36 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $161.35 | 2022 | |
| Pfizer INC. | $157.46 | 2019-2022 | |
| Abbott Laboratories | $123.13 | 2022 | |
| Lilly USA, LLC | $122.89 | 2020-2023 | Mounjaro |
| Amgen INC. | $98.85 | 2020-2022 | |
| Glaxosmithkline, LLC. | $97.19 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $63.92 | 2020-2021 | |
| Astellas Pharma US INC | $52.53 | 2019-2022 | |
| Indivior INC. | $47.22 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.69 | 2022 | |
| Sunovion Pharmaceuticals INC. | $35.67 | 2022 | |
| Boston Scientific Corporation | $30.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.57 | 2021-2022 | |
| Shield Therapeutics INC | $24.84 | 2023 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $20.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.89 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.58 | 2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.56 | 2019 | |
| Eisai INC. | $16.48 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.24 | 2021 | |
| Bardy Diagnostics, INC. | $7.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Marconi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.